Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed to support the early detection and staging of cognitive impairment and dementia, leading to appropriate additional testing for the clinical, biological diagnosis and treatment of dementias such as AD. [Read more…] about Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia
Brain-wave pattern can identify people likely to respond to antidepressant, study finds (Stanford Medicine press release):
“A new method of interpreting brain activity could potentially be used in clinics to help determine the best treatment options for depression, according to a study led by researchers at the Stanford School of Medicine.
Stanford researchers and their collaborators used electroencephalography, a tool for monitoring electrical activity in the brain, and an algorithm to identify a brain-wave signature in [Read more…] about Machine-learning study finds EEG brain signatures that predict response to antidepressant treatments
“WHEN BAKUL PATEL started as a policy advisor in the US Food and Drug Administration in 2008, he could pretty much pinpoint when a product was going to land in front of the reviewers in his division. Back when medical devices were heavy on the hardware—your pacemakers and your IUDs—it would take manufacturers years to get them ready for regulatory approval. FDA reviewers could keep up pretty well [Read more…] about The FDA creates new Digital Health unit to reimagine regulatory paths in the age of scalable, AI-enhanced innovation